{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:42:04Z","timestamp":1774359724072,"version":"3.50.1"},"reference-count":144,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T00:00:00Z","timestamp":1547856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.nefro.2018.10.009","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T08:28:03Z","timestamp":1550651283000},"page":"227-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Osteoporosis, densidad mineral \u00f3sea y complejo CKD-MBD (II): implicaciones terap\u00e9uticas"],"prefix":"10.1016","volume":"39","author":[{"given":"Jordi","family":"Bover","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Ure\u00f1a-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda","family":"Laiz Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep-Vicens","family":"Torregrosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minerva","family":"Rodr\u00edguez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Castro-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"G\u00f3rriz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Benito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"L\u00f3pez-B\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Lloret Cora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Secundino","family":"Cigarr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iara","family":"DaSilva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"S\u00e1nchez-Bay\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mateu Escudero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lluis","family":"Guirado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cannata-And\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2018.10.009_bib0730","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.nefro.2017.12.006","article-title":"Osteoporosis, densidad mineral \u00f3sea y complejo CKD-MBD (I): Consideraciones diagn\u00f3sticas","volume":"38","author":"Bover","year":"2018","journal-title":"Nefrologia."},{"key":"10.1016\/j.nefro.2018.10.009_bib0735","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40620-017-0404-z","article-title":"Osteoporosis, bone mineral density and CKD-MBD: Treatment considerations","volume":"30","author":"Bover","year":"2017","journal-title":"J Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib0740","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/joim.12361","article-title":"How to predict and treat increased fracture risk in chronic kidney disease","volume":"278","author":"West","year":"2015","journal-title":"J Intern Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib0745","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.kint.2017.07.021","article-title":"Fractures in patients with CKD \u2014 diagnosis, treatment, and prevention: A review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation","volume":"92","author":"Pimentel","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib0750","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S2213-8587(17)30310-8","article-title":"Bone and mineral disorders in chronic kidney disease: Implications for cardiovascular health and ageing in the general population","volume":"6","author":"Covic","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.nefro.2018.10.009_bib0755","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2215\/CJN.09500916","article-title":"Fractures in patients with CKD: Time for action","volume":"11","author":"Moe","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib0760","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE trial","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib0765","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"76","year":"2009","journal-title":"Kidney Int Suppl."},{"issue":"Supl 1","key":"10.1016\/j.nefro.2018.10.009_bib0770","first-page":"3","article-title":"Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (SEN-MBD)","volume":"31","author":"Torregrosa","year":"2011","journal-title":"Nefrologia."},{"key":"10.1016\/j.nefro.2018.10.009_bib0775","doi-asserted-by":"crossref","unstructured":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International Suppl.2017;7:1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"10.1016\/j.nefro.2018.10.009_bib0780","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","article-title":"KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"70","author":"Isakova","year":"2017","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2018.10.009_bib0785","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"Komarov","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.nefro.2018.10.009_bib0790","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00198-017-4310-y","article-title":"Spanish consensus on treat to target for osteoporosis","volume":"29","author":"Nogu\u00e9s","year":"2018","journal-title":"Osteoporosis International."},{"key":"10.1016\/j.nefro.2018.10.009_bib0795","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.rce.2015.08.003","article-title":"Clinical practice guidelines for posmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014)","volume":"215","author":"Gonz\u00e1lez-Mac\u00edas","year":"2015","journal-title":"Rev Clin Esp."},{"key":"10.1016\/j.nefro.2018.10.009_bib0800","unstructured":"Calvo Bastida CJ. Gu\u00eda pr\u00e1ctica del manejo de la osteoporosis y de la prevenci\u00f3n de la fractura por fragilidad en atenci\u00f3n primaria. 2012 [consultado 28 Feb 2018]. Disponible en: http:\/\/www.semg.es\/images\/stories\/recursos\/2015\/documentos\/osteoporosis_guia.pdf"},{"key":"10.1016\/j.nefro.2018.10.009_bib0805","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/ki.2013.547","article-title":"The three-year incidence of fracture in chronic kidney disease","volume":"86","author":"Naylor","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib0810","first-page":"849","article-title":"Osteosarcopenia: A new geriatric syndrome","volume":"46","author":"Hassan","year":"2017","journal-title":"Aust Fam Physician."},{"key":"10.1016\/j.nefro.2018.10.009_bib0815","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib0820","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib0825","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMcp1210380","article-title":"Calcium supplements and fracture prevention","volume":"369","author":"Bauer","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib0830","doi-asserted-by":"crossref","first-page":"h4580","DOI":"10.1136\/bmj.h4580","article-title":"Calcium intake and risk of fracture: Systematic review","volume":"351","author":"Bolland","year":"2015","journal-title":"BMJ."},{"key":"10.1016\/j.nefro.2018.10.009_bib0835","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/ajcn\/86.5.1780","article-title":"Calcium intake and hip fracture risk in men and women: A meta-analysis of prospective cohort studies and randomized controlled trials","volume":"86","author":"Bischoff-Ferrari","year":"2007","journal-title":"Am J Clin Nutr."},{"key":"10.1016\/j.nefro.2018.10.009_bib0840","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d2040","article-title":"Calcium supplements with or without vitaminD and risk of cardiovascular events: Reanalysis of the Women's Health Initiative limited access dataset and meta-analysis","volume":"342","author":"Bolland","year":"2011","journal-title":"BMJ."},{"key":"10.1016\/j.nefro.2018.10.009_bib0845","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/jbmr.2311","article-title":"The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: A collaborative meta-analysis of randomized controlled trials","volume":"30","author":"Lewis","year":"2015","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib0850","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.2012.403","article-title":"Oral calcium carbonate affects calcium but not phosphorus balance in stage3-4 chronic kidney disease","volume":"83","author":"Hill","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib0855","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ki.2011.490","article-title":"Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets","volume":"81","author":"Spiegel","year":"2012","journal-title":"Kidney Int."},{"issue":"Suppl 2","key":"10.1016\/j.nefro.2018.10.009_bib0860","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/S1297-319X(12)70017-9","article-title":"Osteoporosis: Chronic kidney disease in rheumatology practice","volume":"79","author":"Cesini","year":"2012","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.nefro.2018.10.009_bib0865","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitaminD from the Institute of Medicine: What clinicians need to know","volume":"96","author":"Ross","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.nefro.2018.10.009_bib0870","first-page":"461","article-title":"Recomendaciones sobre suplementos de vitaminaD y calcio para las personas adultas en Espa\u00f1a","volume":"86","author":"Rigueira Garc\u00eda","year":"2012","journal-title":"Rev Esp Salud Publica."},{"key":"10.1016\/j.nefro.2018.10.009_bib0875","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib0880","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.jrn.2007.10.019","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: Results of a randomized clinical trial","volume":"18","author":"Suki","year":"2008","journal-title":"J Ren Nutr."},{"key":"10.1016\/j.nefro.2018.10.009_bib0885","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/ki.2013.185","article-title":"Use of phosphate-binding agents is associated with a lower risk of mortality","volume":"84","author":"Cannata-Andia","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib0890","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1681\/ASN.2008121277","article-title":"Phosphorus and survival: Key questions that need answers","volume":"20","author":"Cannata-And\u00eda","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib0895","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: An updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.nefro.2018.10.009_bib0900","doi-asserted-by":"crossref","first-page":"e0171028","DOI":"10.1371\/journal.pone.0171028","article-title":"Comparative effectiveness of phosphate binders in patients with chronic kidney disease: A systematic review and network meta-analysis","volume":"12","author":"Sekercioglu","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.nefro.2018.10.009_bib0905","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/ndt\/gfw080","article-title":"Con: Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease","volume":"31","author":"Agarwal","year":"2016","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2018.10.009_bib0910","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ndt\/gfw082","article-title":"Pro: Should we correct vitaminD deficiency\/insufficiency in chronic kidney disease patients with inactive forms of vbitaminD or just treat them with active vitaminD forms?","volume":"31","author":"Goldsmith","year":"2016","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2018.10.009_bib0915","first-page":"108","article-title":"2010 - Gu\u00eda de pr\u00e1ctica cl\u00ednica de la Sociedad Espa\u00f1ola de Di\u00e1lisis y Trasplante de las alteraciones del metabolismo mineral y \u00f3seo de la enfermedad renal cr\u00f3nica (CKD-MBD)","volume":"32","author":"Prados-Garrido","year":"2011","journal-title":"Dial Traspl."},{"key":"10.1016\/j.nefro.2018.10.009_bib0920","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5527\/wjn.v5.i5.471","article-title":"What is the optimal level of vitaminD in non-dialysis chronic kidney disease population?","volume":"5","author":"Molina","year":"2016","journal-title":"World J Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib0925","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa1109617","article-title":"A pooled analysis of vitaminD dose requirements for fracture prevention","volume":"367","author":"Bischoff-Ferrari","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib0930","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1210\/jc.2014-1742","article-title":"The effects of vitaminD on skeletal muscle strength, muscle mass, and muscle power: A systematic review and meta-analysis of randomized controlled trials","volume":"99","author":"Beaudart","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.nefro.2018.10.009_bib0935","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/jcsm.12218","article-title":"VitaminD, a modulator of musculoskeletal health in chronic kidney disease","volume":"8","author":"Molina","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle."},{"key":"10.1016\/j.nefro.2018.10.009_bib0940","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1001\/jama.2017.19344","article-title":"Association between calcium or vitaminD supplementation and fracture incidence in community-dwelling older adults","volume":"318","author":"Zhao","year":"2017","journal-title":"JAMA."},{"key":"10.1016\/j.nefro.2018.10.009_bib0950","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/jbmr.1496","article-title":"Risk factors for prediction of inadequate response to antiresorptives","volume":"27","author":"D\u00edez-P\u00e9rez","year":"2012","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib0955","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2012.03.026","article-title":"25 hydroxyvitaminD serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis","volume":"51","author":"Peris","year":"2012","journal-title":"Bone."},{"key":"10.1016\/j.nefro.2018.10.009_bib0960","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00774-013-0480-7","article-title":"Osteomalacia induced by vitaminD deficiency in hemodialysis patients: The crucial role of vitaminD correction","volume":"32","author":"Mac-Way","year":"2014","journal-title":"J Bone Miner Metab."},{"key":"10.1016\/j.nefro.2018.10.009_bib0965","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00223-018-0399-z","article-title":"Alkaline phosphatases in the complex chronic kidney disease-mineral and bone disorders","volume":"103","author":"Bover","year":"2018","journal-title":"Calcif Tissue Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib0970","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/kisup.2011.28","article-title":"Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: New insights into vitaminD receptor activation","volume":"1","author":"Bover","year":"2011","journal-title":"Kidney Int Suppl."},{"key":"10.1016\/j.nefro.2018.10.009_bib0975","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2215\/CJN.01760215","article-title":"Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism","volume":"11","author":"Bover","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib0980","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2007.110","article-title":"Association of activated vitaminD treatment and mortality in chronic kidney disease","volume":"168","author":"Kovesdy","year":"2008","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib0985","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/ki.2008.343","article-title":"Oral active vitaminD is associated with improved survival in hemodialysis patients","volume":"74","author":"Naves-D\u00edaz","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib0990","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.semnephrol.2014.09.008","article-title":"Adynamic bone disease: From bone to vessels in chronic kidney disease","volume":"34","author":"Bover","year":"2014","journal-title":"Semin Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib0995","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"VitaminD therapy and cardiac structure and function in patients with chronic kidney disease","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA."},{"key":"10.1016\/j.nefro.2018.10.009_bib1000","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/ndt\/gfl567","article-title":"Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitaminD (PRIUS-CKD)","volume":"22","author":"Fujii","year":"2007","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2018.10.009_bib1005","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.nefro.2018.10.009_bib1010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jbmr.5650070507","article-title":"Retention of etidronate in human, dog, and rat","volume":"7","author":"Kasting","year":"1992","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib1015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2010.08.008","article-title":"Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability","volume":"49","author":"Bellido","year":"2011","journal-title":"Bone."},{"key":"10.1016\/j.nefro.2018.10.009_bib1020","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet."},{"key":"10.1016\/j.nefro.2018.10.009_bib1025","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA."},{"key":"10.1016\/j.nefro.2018.10.009_bib1030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib1035","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib1040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2215\/CJN.02550508","article-title":"Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue","volume":"4","author":"Toussaint","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib1045","first-page":"115","article-title":"Osteoporosis in end-state renal disease","volume":"19","author":"Lindberg","year":"1999","journal-title":"Semin Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib1050","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial","volume":"22","author":"Jamal a","year":"2007","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib1055","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib1060","article-title":"Interventions for preventing bone disease in kidney transplant recipients","volume":"18","author":"Palmer","year":"2007","journal-title":"Cochrane Database Syst Rev;"},{"key":"10.1016\/j.nefro.2018.10.009_bib1065","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/M16-2752","article-title":"Benefits and harms of osteoporosis medications in patients with chronic kidney disease: A systematic review and meta-analysis","volume":"166","author":"Wilson","year":"2017","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib1070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1759720X13477714","article-title":"Bisphosphonate drug holiday: Who, when and how long","volume":"5","author":"Diab","year":"2013","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"10.1016\/j.nefro.2018.10.009_bib1075","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: Report of a Task Force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib1080","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1302\/2046-3758.63.BJR-2016-0125.R1","article-title":"Bisphosphonates and atypical subtrochanteric fractures of the femur","volume":"6","author":"Kharwadkar","year":"2017","journal-title":"Bone Jt Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib1085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/2040622315584114","article-title":"Atypical femoral fractures and bisphosphonate use: Current evidence and clinical implications","volume":"6","author":"Saita","year":"2015","journal-title":"Ther Adv Chronic Dis."},{"key":"10.1016\/j.nefro.2018.10.009_bib1090","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: A potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.nefro.2018.10.009_bib1095","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMc062268","article-title":"Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis","volume":"355","author":"Armamento-Villareal","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib1100","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.bone.2003.08.004","article-title":"Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs","volume":"33","author":"Burr","year":"2003","journal-title":"Bone."},{"key":"10.1016\/j.nefro.2018.10.009_bib1105","first-page":"43399","article-title":"Long-term effects of bisphosphonate therapy: Perforations, microcracks and mechanical properties","volume":"7","author":"Ma","year":"2017","journal-title":"Sci Reports."},{"key":"10.1016\/j.nefro.2018.10.009_bib1110","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA."},{"key":"10.1016\/j.nefro.2018.10.009_bib1115","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur","volume":"362","author":"Black","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib1120","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib1125","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1359\/jbmr.070609","article-title":"Microcrack Frequency and Bone Remodeling in Postmenopausal Osteoporotic Women on Long-Term Bisphosphonates: A bone biopsy study","volume":"22","author":"Chapurlat","year":"2007","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib1130","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone."},{"key":"10.1016\/j.nefro.2018.10.009_bib1135","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMp1202619","article-title":"Bisphosphonates for osteoporosis \u2014 Where do we go","volume":"366","author":"Whitaker","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib1140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib1145","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.nefro.2018.10.009_bib1150","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000276666","article-title":"Bisphosphonate use in chronic kidney disease: Association with adynamic bone disease in a bone histology series","volume":"29","author":"Amerling","year":"2010","journal-title":"Blood Purif."},{"key":"10.1016\/j.nefro.2018.10.009_bib1155","first-page":"317","article-title":"Fractures in chronic kidney disease: Pursuing the best screening and management","volume":"24","author":"Jamal","year":"2015","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"10.1016\/j.nefro.2018.10.009_bib1160","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1097\/01.ASN.0000087092.53894.80","article-title":"Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate","volume":"14","author":"Coco","year":"2003","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib1165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5301\/jn.5000212","article-title":"Osteoporosis and adynamic bone in chronic kidney disease","volume":"26","author":"Cannata-And\u00eda","year":"2013","journal-title":"J Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib1170","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.kint.2015.12.004","article-title":"Changing bone patterns with progression of chronic kidney disease","volume":"89","author":"Dr\u00fceke","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib1175","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.kint.2016.01.024","article-title":"Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease","volume":"90","author":"Carrillo-L\u00f3pez","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib1180","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.kint.2016.06.041","article-title":"Parathyroid hormone metabolism and signaling in health and chronic kidney disease","volume":"90","author":"Evenepoel","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib1185","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfr317","article-title":"Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients-a single-center cohort study","volume":"27","author":"Iimori","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2018.10.009_bib1190","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2215\/CJN.06040614","article-title":"Comparison of fracture risk prediction among individuals with reduced and normal kidney function","volume":"10","author":"Naylor","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib1195","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jbmr.2406","article-title":"Bone mineral density predicts fractures in chronic kidney disease","volume":"30","author":"West","year":"2015","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib1200","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2215\/CJN.12871211","article-title":"Bone mineral density and fracture risk in older individuals with CKD","volume":"7","author":"Yenchek","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib1205","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1093\/ndt\/gfr591","article-title":"The connections between vascular calcification and bone health","volume":"26","author":"Cannata-Andia","year":"2011","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2018.10.009_bib1210","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00198-007-0539-1","article-title":"Progression of vascular calcifications is associated with greater bone loss and increased bone fractures","volume":"19","author":"Naves","year":"2008","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib1215","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ndt\/gfn466","article-title":"Vascular calcifications, vertebral fractures and mortality in haemodialysis patients","volume":"24","author":"Rodr\u00edguez-Garc\u00eda","year":"2009","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2018.10.009_bib1220","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jacc.2010.05.050","article-title":"Bisphosphonate use and prevalence of valvular and vascular calcification in women: MESA (The Multi-Ethnic Study of Atherosclerosis)","volume":"56","author":"Elmariah","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.nefro.2018.10.009_bib1225","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00044011-200626040-00006","article-title":"Effect of etidronic acid on arterial calcification in dialysis patients","volume":"26","author":"Ariyoshi","year":"2006","journal-title":"Clin Drug Investig."},{"key":"10.1016\/j.nefro.2018.10.009_bib1230","first-page":"329","article-title":"Tratamiento eficaz de la arteriolopat\u00eda ur\u00e9mica calcificante con bifosfonatos","volume":"32","author":"Torregrosa","year":"2012","journal-title":"Nefrologia."},{"key":"10.1016\/j.nefro.2018.10.009_bib1235","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-016-3607-6","article-title":"Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: A systematic review and meta-analysis","volume":"27","author":"Beaudoin","year":"2016","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib1240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11914-009-0004-5","article-title":"Denosumab: Anti-RANKL antibody","volume":"7","author":"Miller","year":"2009","journal-title":"Curr Osteoporos Rep."},{"key":"10.1016\/j.nefro.2018.10.009_bib1245","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the FREEDOM extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib1250","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jocd.2016.01.004","article-title":"Response to therapy with teriparatide, denosumab, or both in postmenopausal women in the DATA (Denosumab and Teriparatide Administration) study randomized controlled trial","volume":"19","author":"Leder","year":"2016","journal-title":"J Clin Densitom."},{"key":"10.1016\/j.nefro.2018.10.009_bib1255","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib1260","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/imj.12283","article-title":"Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure","volume":"43","author":"Farinola","year":"2013","journal-title":"Intern Med J."},{"key":"10.1016\/j.nefro.2018.10.009_bib1265","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000380960","article-title":"Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5","volume":"41","author":"Dave","year":"2015","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib1270","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/nep.12432","article-title":"Hypocalcaemic tetany occurring post a single denosumab dose in a patient with stage 4 chronic kidney disease, followed by calcium- and calcitriol-induced hypercalcaemia","volume":"20","author":"Lambe","year":"2015","journal-title":"Nephrology."},{"key":"10.1016\/j.nefro.2018.10.009_bib1275","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib1280","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40620-016-0334-1","article-title":"Safety and efficacy of denosumab in osteoporotic hemodialysed patients","volume":"30","author":"Festuccia","year":"2017","journal-title":"J Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib1285","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.nefro.2017.01.004","article-title":"Denosumab y enfermedad renal cr\u00f3nica avanzada: hipocalcemia severa con riesgo vital","volume":"38","author":"Monge Rafael","year":"2018","journal-title":"Nefrologia."},{"key":"10.1016\/j.nefro.2018.10.009_bib1290","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1053\/j.ajkd.2015.03.012","article-title":"Denosumab for low bone mass in hemodialysis patients: A noncontrolled trial","volume":"66","author":"Hiramatsu","year":"2015","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2018.10.009_bib1295","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jbmr.2043","article-title":"RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk","volume":"29","author":"Samelson","year":"2014","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib1300","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2169\/internalmedicine.54.4946","article-title":"Rapid progression of vascular and soft tissue calcification while being managed for severe and persistent hypocalcemia induced by denosumab treatment in a patient with multiple myeloma and chronic kidney disease","volume":"54","author":"Ueki","year":"2015","journal-title":"Intern Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib1305","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1210\/jc.2014-1154","article-title":"An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis","volume":"99","author":"Chen","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"Suppl 1","key":"10.1016\/j.nefro.2018.10.009_bib1310","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s10157-016-1368-3","article-title":"Chronic kidney disease and fragility fracture","volume":"21","author":"Kazama","year":"2017","journal-title":"Clin Exp Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib1315","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1053\/j.ajkd.2013.12.018","article-title":"Bone disease in CKD: A focus on osteoporosis diagnosis and management","volume":"64","author":"Miller","year":"2014","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2018.10.009_bib1320","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1053\/j.ajkd.2013.12.016","article-title":"Fragility fractures and osteoporosis in CKD: Pathophysiology and diagnostic methods","volume":"63","author":"Salam","year":"2014","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2018.10.009_bib1325","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib1330","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","article-title":"Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up)","volume":"98","author":"Leder","year":"2017","journal-title":"Bone."},{"key":"10.1016\/j.nefro.2018.10.009_bib1335","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib1340","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2147\/CIA.S120175","article-title":"Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: Post hoc analysis of a postmarketing observational study","volume":"11","author":"Nishikawa","year":"2016","journal-title":"Clin Interv Aging."},{"key":"10.1016\/j.nefro.2018.10.009_bib1345","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000316708","article-title":"Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): A pilot study","volume":"33","author":"Cejka","year":"2010","journal-title":"Kidney Blood Press Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib1350","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/ckj\/sfv005","article-title":"Treatment of adynamic bone disease in a haemodialysis patient with teriparatide","volume":"8","author":"Giamalis","year":"2015","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.nefro.2018.10.009_bib1355","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA."},{"key":"10.1016\/j.nefro.2018.10.009_bib1360","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","article-title":"Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: A prospective study","volume":"27","author":"Sumida","year":"2016","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib1365","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib1370","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMe1711298","article-title":"Romosozumab \u2014 Promising or practice changing?","volume":"377","author":"Rosen","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib1375","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib1380","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2018.10.009_bib1385","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jbmr.2372","article-title":"Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy","volume":"30","author":"Moe","year":"2015","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.nefro.2018.10.009_bib1390","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ackd.2007.01.002","article-title":"Sexual function in chronic kidney disease","volume":"14","author":"Anantharaman","year":"2007","journal-title":"Adv Chronic Kidney Dis."},{"key":"10.1016\/j.nefro.2018.10.009_bib1395","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA."},{"key":"10.1016\/j.nefro.2018.10.009_bib1400","first-page":"461","article-title":"Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5","volume":"8","author":"Haghverdi","year":"2014","journal-title":"Iran J Kidney Dis."},{"key":"10.1016\/j.nefro.2018.10.009_bib1405","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1046\/j.1523-1755.2003.00005.x","article-title":"Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis","volume":"63","author":"Hern\u00e1ndez","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib1410","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1681\/ASN.2007050555","article-title":"The effect of raloxifene treatment in postmenopausal women with CKD","volume":"19","author":"Ishani","year":"2008","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib1415","doi-asserted-by":"crossref","first-page":"423","DOI":"10.5414\/CNP72423","article-title":"Raloxifene ameliorates progressive bone loss in postmenopausal dialysis patients with controlled parathyroid hormone levels","volume":"72","author":"Eriguchi","year":"2009","journal-title":"Clin Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib1420","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ki.2014.349","article-title":"Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism","volume":"87","author":"Behets","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.009_bib1425","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1681\/ASN.2007010022","article-title":"Fracture risk after parathyroidectomy among chronic hemodialysis patients","volume":"18","author":"Rudser","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib1430","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2265.2011.04265.x","article-title":"Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism","volume":"76","author":"Lu","year":"2012","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.1016\/j.nefro.2018.10.009_bib1435","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.03520414","article-title":"Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis","volume":"10","author":"Ishani","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.009_bib1440","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/S0140-6736(05)66782-7","article-title":"Calcimimetics and calcilytics \u2014 Fooling the calcium receptor","volume":"365","author":"Steddon","year":"2005","journal-title":"Lancet."},{"key":"10.1016\/j.nefro.2018.10.009_bib1445","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/cen.12549","article-title":"Adverse skeletal effects of drugs \u2014 Beyond glucocorticoids","volume":"82","author":"O'Sullivan","year":"2015","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.1016\/j.nefro.2018.10.009_bib1450","doi-asserted-by":"crossref","first-page":"450","DOI":"10.5301\/jn.5000188","article-title":"Bisphosphonate therapy in renal osteodystrophy \u2014 A review","volume":"26","author":"Bergner","year":"2013","journal-title":"J Nephrol."}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519300128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519300128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:53:48Z","timestamp":1759323228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699519300128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":144,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0211699519300128"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2018.10.009","relation":{},"ISSN":["0211-6995"],"issn-type":[{"value":"0211-6995","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoporosis, densidad mineral \u00f3sea y complejo CKD-MBD (II): implicaciones terap\u00e9uticas","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2018.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}